HMGCR and coronary artery disorder: Lankin et al. described the interesting findings that therapy with a 3-hydroxy-3-methylglutaryl-coenzyme A-reductase inhibitor (simvastatin) is associated with the intense accumulation of peroxidation products on the LDL of patients with coronary heart disease, despite having a decreased cholesterol level [33].